v3.26.1
Segment Information - Schedule of Reportable Segment Revenue, Operating Expenses, and Net Loss (Detail) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue:    
License and other revenue $ 3,000 $ 7,679
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember
Total revenue $ 3,000 $ 7,679
Research and development expenses    
General and administrative expenses 11,027 18,739
Other segment expenses (income)    
Depreciation expense 504 1,208
Stock compensation expense 10,537 19,325
Interest income (5,352) (7,813)
Other expense 53 9
Reconciliation to consolidated net loss:    
Net loss (73,291) (77,065)
Operating Segments [Member]    
Revenue:    
License and other revenue $ 3,000 $ 7,679
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember
Research and development expenses    
General and administrative expenses $ 7,117 $ 10,925
Other segment expenses (income)    
Depreciation expense 504 1,208
Interest income (5,352) (7,813)
Other expense 53 9
Segment net loss (73,291) (77,065)
Operating Segments [Member] | Research and Development Expense [Member]    
Research and development expenses    
External costs for programs in clinical trials 41,383 23,673
External costs for platform technologies and preclinical programs 3,691 14,638
Employee related expenses 14,339 17,011
Other expenses 4,019 5,768
Other segment expenses (income)    
Stock compensation expense 6,690 11,689
Operating Segments [Member] | General and Administrative Expenses [Member]    
Other segment expenses (income)    
Stock compensation expense $ 3,847 $ 7,636